Safety reports related to alirocumab and evolocumab and the occurrence of neuropsychiatric adverse drug reactions (ADRs) were retrieved from the Eudravigilance database and then analyzed.

ADRs most commonly identified for alirocumab and evolocumab were headache, insomnia and depression. The statistical analysis applied revealed no difference between alirocumab and evolocumab and the probability of neuropsychiatric ADRs.

Further data from real-life contexts needs to be collected in order to better characterize the neurocognitive safety profile of alirocumab and evolocumab.